Eli Lilly

Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Mon, 06/10/19 - 09:39 am
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Mon, 06/10/19 - 09:27 am
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Eli Lilly throws SCOTUS hail mary in Cialis patent infringement fight
Fierce Pharma
Fri, 06/7/19 - 12:04 pm
Eli Lilly
Cialis
patents
Patent Infringement
benign prostatic hyperplasia
Supreme Court
Eli Lilly Takes Aim at Chronic Pain Problem, Alleviating Opiate Addiction
TheStreet.com
Thu, 06/6/19 - 09:36 am
Eli Lilly
Emgality
cluster headaches
Lilly's scored its cluster headache nod for Emgality. Will it shake up the CGRP race?
Fierce Pharma
Wed, 06/5/19 - 12:04 am
Eli Lilly
Emgality
cluster headaches
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Fierce Pharma
Wed, 06/5/19 - 12:03 am
China
Sanofi
Eli Lilly
Bristol-Myers Squibb
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers
BioCentury
Mon, 06/3/19 - 11:25 am
Blueprint Medicines
BLU-667
ASCO 2019
Eli Lilly
RET-altered cancer
LOXO-292
A bruised Eli Lilly buys rights to Centrexion’s early-stage pain drug for $47.5M upfront
Endpoints
Tue, 05/28/19 - 10:09 am
Eli Lilly
non-opioid pain treatments
Centrexion
CNTX-0290
Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart
BioSpace
Thu, 05/23/19 - 12:28 pm
Eli Lilly
drug pricing
generics
insulin
diabetes
Lispro
KwikPens
Lilly’s Mirikizumab succeeds in phase 2 study in Crohn’s disease
Pharmaceutical Business Review
Wed, 05/22/19 - 09:55 am
Eli Lilly
Crohn's Disease
mirikizumab
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 05/19/19 - 03:59 pm
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
3 Top Diabetes Stocks to Watch in May
Motley Fool
Wed, 05/15/19 - 10:29 am
diabetes
AstraZeneca
Eli Lilly
Medtronic
How can Teva's migraine drug face off Amgen and Lilly? Put neurologists first, DTC last, executive says
Fierce Pharma
Tue, 05/14/19 - 04:55 pm
Teva Pharmaceutical
migraines
Ajovy
Amgen
Eli Lilly
Emgality
Aimovig
neurologists
physicians
DTC advertising
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Tue, 05/14/19 - 09:56 am
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Pharmaforum
Mon, 05/13/19 - 10:07 am
Eli Lilly
Cyramza
FDA
liver cancer
hepatocellular carcinoma
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
Yahoo/Reuters
Sat, 05/11/19 - 12:10 pm
Eli Lilly
Amgen
Teva Pharmaceutical
migraines
Emgality
Aimovig
Researchers warn about gangrene cases in patients on SGLT2 diabetes drugs
Fierce Pharma
Thu, 05/9/19 - 11:04 pm
gangrene
diabetes
JNJ
Invokana
AstraZeneca
Farxiga
Eli Lilly
Boehringer Ingelheim
Jardiance
Eli Lilly's Emgality shows positive Phase 3 results in treatment of migraine
Pharmafile
Wed, 05/8/19 - 05:39 pm
Eli Lilly
migraines
clinical trials
Emgality
ED Drug Shows Promise in Sheep Heart Failure Study
BioSpace
Mon, 05/6/19 - 10:48 am
heart failure
tadalafil
Pfizer
Viagra
Eli Lilly
Cialis

Pages